Interní Med. 2008; 10(5): 240-244

age-related macular degeneration

MUDr. Jan Studnička Ph.D
Oční klinika LF a FN UK, Hradec Králové

Age-related macular degeneration is the most frequent cause of severe visual lost in people older than 55 years in industrial countries. The disease has two variants, dry and wet forms. The wet form develops only in 10–20 %, but without treatment causes in 80–90 % practical blindness. Symptoms of the disease are visual impairment, metamorphopsias and central visual field defect. Actual therapy stabilize the disease in 70–90 % of patients and in 30 % of patients even improves their visual functions. The important part of treatment is prevention of risk factors (smoking, insolation, higher intake of specific types of fat…).

Keywords: age-related macular degeneration, choroidal neovascularisation, retinal pigment epithelium

Published: June 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Studnička J. age-related macular degeneration. Interní Med. 2008;10(5):240-244.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Age-Related Eye Disease Study Research Group (2001). A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta karotene and zinc for agerelated macular degeneration and vision loss. AREDS Report 8. Arch Ophthalmol 119: 1417-1436. Go to original source... Go to PubMed...
    2. Boyer DS, Antoszyk AN, Awh CC, a kol. Subgroup Analysis of the MARINA Study of Ranibizumab in Neovascular Age-Related Macular Degeneration. Ophthalmology 2007; 114: 246-252. Go to original source... Go to PubMed...
    3. Brown MM, Brown GC, Stein JD, a kol. Age-related macular degeneration: economic burden and value-based medicine analysis. Can J Ophthalmol 2005; 40: 277-287. Go to original source... Go to PubMed...
    4. Brown DM, Kaiser PK, Michels M, a kol. Ranibizumab versus Verteporfin for neovascular agerelated macular degeneration. N Engl J Med 2006; 355: 1432-1444. Go to original source... Go to PubMed...
    5. Kaiser PK. Perspective antivascular endothelial growth factor agents and thein development: Therapeutic implications in ocular diseases. Am J Ophthalmol 2006; 142: 660-668. Go to original source... Go to PubMed...
    6. Kaiser PK. Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension. TAP Report No. 8. Graefe´s Arch Clin Exp Ophthalmol DOI 10. 1007/s00417-005-0199-9.
    7. Landy J, Brown GC. Update on photodynamic therapy. Curr Opin Ophthalmol, 2003; 14: 163-168. Go to original source... Go to PubMed...
    8. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Update findings from two clinical trials. Arch Ophthalmol. 1993; 111: 1200-1209. Go to original source... Go to PubMed...
    9. Newsom RS, McAlister JC, Saeed M, et al. Results 28 months following transpupillary thermotherapy for classic and occult choroidal neovascularization in patiens with age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005; 36 (2): 94-102. Go to original source...
    10. Pulido JS, Winters JL, Boyer D. Preliminary analysis of the final multicenter investigation of rheopheresis for age related macular degeneration (AMD) trial (MIRA-1) results. Trans Am Ophthalmol Soc, 2006; 104: 221-231. Go to PubMed...
    11. Radiation Therapy for Age-related Macular Degeneration (1999). A prospective, randomized, double-masked trial on radiation therapy for neovascular age-related macular degeneration (RAD Study). Ophthalmology 106: 2239-2247. Go to original source... Go to PubMed...
    12. Reichel E, Berrocal AM, Ip M, et al. Transpupillary thermotherapy of occult subfoveal choroidal neovascularization in patients with age-related macular degeneration. Ophthalmology, 1999; 106 (10): 1908-1914. Go to original source... Go to PubMed...
    13. Richer S, Stiles W, Statkute L, et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry, 2004; 75 (4): 216-230. Go to original source... Go to PubMed...
    14. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci. 2001; 114: 853-865. Go to original source... Go to PubMed...
    15. Rosenfeld P, Brown DM, Heier JS, a kol. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431. Go to original source... Go to PubMed...
    16. Submacular Surgery Trials (SST) research group (2004). Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST Report 13. Ophthalmology 111, 1993-2006. Go to original source... Go to PubMed...
    17. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond). 2005, 109: 227-241. Go to original source... Go to PubMed...
    18. Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group (2005): Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: four-year results of an open-label extension of 2 randomized clinical trials-TAP Report No. 7 Arch Ophthalmol 123: 1283-1285. Go to original source... Go to PubMed...
    19. VEGF Inhibition Study in Ocular Neovascularization (V. I. S. I. O. N) Clinical Trial Group: Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular agerelated macular degeneration. Ophthalmology 2006; 113: 1508-1521. Go to original source... Go to PubMed...
    20. Virgili G, Do DV, Bressler NM, a kol. New therapies for neovascular age-related macular degeneration: critical appraisal of the current evidence. Acta Ophthalmol. Scand. 2007; 85: 6-20. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.